Three, six, or twelve months of dual antiplatelet therapy after DES implantation in patients with or without acute coronary syndromes: an individual patient data pairwise and network meta-analysis of six randomized trials and 11 473 patients.

Should we reconsider dual antiplatelet therapy duration following bioresorbable scaffold angioplasty? J Thorac Dis (2017) 0.75

Mortality in patients treated with extended duration dual antiplatelet therapy after drug-eluting stent implantation: a pairwise and Bayesian network meta-analysis of randomised trials. Lancet (2015) 3.80

Short- versus long-term dual antiplatelet therapy after drug-eluting stent implantation: an individual patient data pairwise and network meta-analysis. J Am Coll Cardiol (2015) 2.82

Coronary artery bypass grafting vs. percutaneous coronary intervention for patients with three-vessel disease: final five-year follow-up of the SYNTAX trial. Eur Heart J (2014) 2.31

Transapical versus transfemoral aortic valve implantation: a multicenter collaborative study. Ann Thorac Surg (2013) 2.14

6- versus 24-month dual antiplatelet therapy after implantation of drug-eluting stents in patients nonresistant to aspirin: the randomized, multicenter ITALIC trial. J Am Coll Cardiol (2014) 1.62

Smoking is associated with adverse clinical outcomes in patients undergoing revascularization with PCI or CABG: the SYNTAX trial at 5-year follow-up. J Am Coll Cardiol (2015) 1.56

Transcatheter aortic valve implantation with the Edwards SAPIEN versus the Medtronic CoreValve Revalving system devices: a multicenter collaborative study: the PRAGMATIC Plus Initiative (Pooled-RotterdAm-Milano-Toulouse In Collaboration). J Am Coll Cardiol (2013) 0.98

A prospective randomized evaluation of the TriGuard™ HDH embolic DEFLECTion device during transcatheter aortic valve implantation: results from the DEFLECT III trial. Eur Heart J (2015) 0.82

Network meta-analysis for evidence synthesis: what is it and why is it posed to dominate cardiovascular decision making? Int J Cardiol (2015) 0.81

Treatment of drug-eluting stent restenosis: Comparison between drug-eluting balloon versus second-generation drug-eluting stents from a retrospective observational study. Catheter Cardiovasc Interv (2015) 0.81

Short-term and long-term clinical impact of stent thrombosis and graft occlusion in the SYNTAX trial at 5 years: Synergy Between Percutaneous Coronary Intervention with Taxus and Cardiac Surgery trial. J Am Coll Cardiol (2013) 0.81

ACS and STEMI treatment: gender-related issues. EuroIntervention (2012) 0.80

Physiological and clinical relevance of anomalous right coronary artery originating from left sinus of Valsalva in adults. Heart (2015) 0.80

Concomitant proton-pump inhibitor use, platelet activity, and clinical outcomes in patients with acute coronary syndromes treated with prasugrel versus clopidogrel and managed without revascularization: insights from the Targeted Platelet Inhibition to Clarify the Optimal Strategy to Medically Manage Acute Coronary Syndromes trial. Am Heart J (2015) 0.79

Impact of Clinical Presentation (Stable Angina Pectoris vs Unstable Angina Pectoris or Non-ST-Elevation Myocardial Infarction vs ST-Elevation Myocardial Infarction) on Long-Term Outcomes in Women Undergoing Percutaneous Coronary Intervention With Drug-Eluting Stents. Am J Cardiol (2015) 0.79

Comparison of percutaneous coronary intervention (with drug-eluting stents) versus coronary artery bypass grafting in women with severe narrowing of the left main coronary artery (from the Women-Drug-Eluting stent for LefT main coronary Artery disease Registry). Am J Cardiol (2014) 0.78

One-year outcome of biolimus eluting stent with biodegradable polymer in all comers: the Italian Nobori Stent Prospective Registry. Int J Cardiol (2014) 0.78

Treatment of Heart Failure With Associated Functional Mitral Regurgitation Using the ARTO System: Initial Results of the First-in-Human MAVERIC Trial (Mitral Valve Repair Clinical Trial). JACC Cardiovasc Interv (2015) 0.78

Modified contrast microinjection technique to facilitate chronic total occlusion recanalization. Catheter Cardiovasc Interv (2015) 0.77

Acute management of stroke patients taking non-vitamin K antagonist oral anticoagulants Addressing Real-world Anticoagulant Management Issues in Stroke (ARAMIS) Registry: Design and rationale. Am Heart J (2016) 0.76

Efficacy and Safety of Dual Antiplatelet Therapy After Complex PCI. J Am Coll Cardiol (2016) 0.76

Relationship of Platelet Reactivity With Bleeding Outcomes During Long-Term Treatment With Dual Antiplatelet Therapy for Medically Managed Patients With Non-ST-Segment Elevation Acute Coronary Syndromes. J Am Heart Assoc (2016) 0.75

Temporal Trends in Care and Outcomes of Patients Receiving Fibrinolytic Therapy Compared to Primary Percutaneous Coronary Intervention: Insights From the Get With The Guidelines Coronary Artery Disease (GWTG-CAD) Registry. J Am Heart Assoc (2016) 0.75

Considerations on the poor discriminatory power of the FRANCE-2 risk score: Authors' reply. Heart (2014) 0.75

TCT-205 Incidence and clinical outcomes associated with DAPT discontinuation in complex PCI patients: From the PARIS registry. J Am Coll Cardiol (2016) 0.75

Transcatheter aortic valve implantation in patients with severe aortic valve stenosis and large aortic annulus, using the self-expanding 31-mm Medtronic CoreValve prosthesis: first clinical experience. J Thorac Cardiovasc Surg (2013) 0.75

Corrigendum to "Safety and efficacy of the COMBO bio-engineered stent in an all-comer PCI cohort: 1-year final clinical outcomes from the MASCOT post-marketing registry" [Int. J. Cardiol. 283 (2019) 67-72]. Int J Cardiol (2019) 0.75

TCT-213 Efficacy and Safety of Long- Versus Short-Term Dual Antiplatelet Therapy Following Complex Percutaneous Coronary Intervention with Drug-Eluting Stents: A Collaborative Patient-Level Pooled Analysis of Randomized Controlled Trials. J Am Coll Cardiol (2016) 0.75

TCT-66 Effects of dual antiplatelet therapy cessation among patients with diabetes mellitus after PCI with DES. J Am Coll Cardiol (2016) 0.75

Transfemoral transcatheter aortic valve implantation in patients with small diseased peripheral vessels. Cardiovasc Revasc Med (2015) 0.75

Heart failure medications prescribed at discharge for patients with left ventricular assist devices. Am Heart J (2016) 0.75

Antithrombotic Approaches in Acute Coronary Syndromes: Optimizing Benefit vs Bleeding Risks. Mayo Clin Proc (2016) 0.75

TCT-265 One-year Outcome of Polymer-free Amphilimus-eluting Stent versus Biodegradable Polymer Biolimus-eluting Stent in Diabetes Mellitus Patients. Propensity-Matched Analysis of the ASTUTE (AmphilimuS iTalian mUlticenTre rEgistry) and INSPIRE-1 (Italian Nobori Stent ProspectIve REgistry-1) Registries. J Am Coll Cardiol (2016) 0.75

A novel maneuver to facilitate retrograde wire externalization during retrograde chronic total occlusion percutaneous coronary intervention. Catheter Cardiovasc Interv (2016) 0.75

Impact of diabetes mellitus on female subjects undergoing transcatheter aortic valve implantation: Insights from the WIN-TAVI international registry. Int J Cardiol (2020) 0.75

TCT-229 Safety and Efficacy of Rotational Atherectomy for the Treatment of Undilatable Underexpanded Stents Implanted in Calcific Lesions. J Am Coll Cardiol (2016) 0.75

TCT-698 Comparison of the fully repositionable and retrievable Lotus Valve and Direct Flow Medical Valve for the treatment of severe aortic stenosis: a high-volume single center experience. J Am Coll Cardiol (2016) 0.75

TCT-361 Targeting Transradial Approach: an Updated Systematic Review and Meta-Analysis of Randomized Controlled Trials. J Am Coll Cardiol (2016) 0.75

TCT-211 Incidence and Impact of Dual Antiplatelet Therapy Cessation on Clinical Outcomes in Patients with Renal Dysfunction: Insights from the PARIS Registry. J Am Coll Cardiol (2016) 0.75

Long-term Safety and Efficacy of New-Generation Drug-Eluting Stents in Women With Acute Myocardial Infarction: From the Women in Innovation and Drug-Eluting Stents (WIN-DES) Collaboration. JAMA Cardiol (2017) 0.75

Bleeding-Related Deaths in Relation to the Duration of Dual-Antiplatelet Therapy After Coronary Stenting. J Am Coll Cardiol (2017) 0.75

TCT-718 Predictors of vascular complications in women undergoing contemporary transcatheter aortic valve replacement: A report from the WIN-TAVI registry. J Am Coll Cardiol (2016) 0.75

Compliance with guideline-directed therapy in diabetic patients admitted with acute coronary syndrome: Findings from the American Heart Association's Get With The Guidelines-Coronary Artery Disease (GWTG-CAD) program. Am Heart J (2017) 0.75

Immediate and 12-Month Outcomes of Ischemic Versus Nonischemic Functional Mitral Regurgitation in Patients Treated With MitraClip (from the 2011 to 2012 Pilot Sentinel Registry of Percutaneous Edge-To-Edge Mitral Valve Repair of the European Society of Cardiology). Am J Cardiol (2016) 0.75

TCT-219 Influence Of Anemia On Physician-Recommended DAPT Discontinuation After Percutaneous Coronary Intervention. J Am Coll Cardiol (2016) 0.75

TCT-437 Clinical outcome of coronary bifurcation management with a "fully bioresorbable" technique. Results of the multicentre BBS study. J Am Coll Cardiol (2016) 0.75

Right ventricular evaluation to improve survival outcome in patients with severe functional mitral regurgitation and advanced heart failure undergoing MitraClip therapy. Int J Cardiol (2016) 0.75

Geographical Variations in Patterns of DAPT Cessation and Two-Year PCI Outcomes: Insights from the PARIS Registry. Thromb Haemost (2019) 0.75

TCT-351 Coronary sinus reducer implantation for the treatment of chronic refractory angina: a single center experience. J Am Coll Cardiol (2016) 0.75

Cangrelor reduces the risk of ischemic complications in patients with single-vessel and multi-vessel disease undergoing percutaneous coronary intervention: Insights from the CHAMPION PHOENIX trial. Am Heart J (2017) 0.75

TCT-420 Incidence of side branch occlusions following bioresorbable scaffold implantation for long left anterior descending artery lesions. J Am Coll Cardiol (2016) 0.75

Transcatheter valve interventions: playground for cardiologists or cardiac surgeons? The cardiologist's view. EuroIntervention (2015) 0.75

TCT-475 Effect of Stent Diameter in Women Undergoing Percutaneous Coronary Intervention with Early- and New-Generation Drug-Eluting Stents: From the Women in Innovation and Drug-Eluting Stents (WIN-DES) Collaboration. J Am Coll Cardiol (2016) 0.75

Short-versus long-term Dual Antiplatelet therapy after drug-eluting stent implantation in women versus men: A sex-specific patient-level pooled-analysis of six randomized trials. Catheter Cardiovasc Interv (2016) 0.75

TCT-453 Correlates and Impact of Coronary Artery Calcifications in Women Undergoing Percutaneous Coronary Intervention with Drug-Eluting Stents: From the Women in Innovation and Drug-Eluting Stents (WIN-DES) Collaboration. J Am Coll Cardiol (2016) 0.75

TCT-206 Tailoring the Intensity of Antiplatelet Pharmacotherapy to Ischemic and Bleeding Risk: A Cost Optimizing Simulation From PARIS. J Am Coll Cardiol (2016) 0.75

The Practice Pattern of Percutaneous Coronary Intervention in Korea: Based on Year 2014 Cohort of Korean Percutaneous Coronary Intervention (K-PCI) Registry. Korean Circ J (2017) 0.75

The Current Status of Percutaneous Coronary Intervention in Korea: Based on Year 2014 Cohort of Korean Percutaneous Coronary Intervention (K-PCI) Registry. Korean Circ J (2017) 0.75

Derivation and validation of the predicting bleeding complications in patients undergoing stent implantation and subsequent dual antiplatelet therapy (PRECISE-DAPT) score: a pooled analysis of individual-patient datasets from clinical trials. Lancet (2017) 0.75

TCT-204 Optimal duration of dual antiplatelet therapy (DAPT) after second generation drug-eluting stent (DES) implantation in elderly patients: the SECURITY-ELDERLY substudy. J Am Coll Cardiol (2016) 0.75

High screen failure rate in patients with resistant hypertension: Findings from SYMPLICITY HTN-3. Am Heart J (2017) 0.75

TCT-400 The importance of implantation technique in ensuring optimal outcomes after bioresorbable scaffold implantation: implications from a real-world cohort. J Am Coll Cardiol (2016) 0.75

A double-blind randomised study to evaluate the efficacy and safety of bindarit in preventing coronary stent restenosis. EuroIntervention (2016) 0.75

TCT-506 Coronary sinus reduction improves myocardial perfusion reserve index assessed by dipyridamole stress cardiac magnetic resonance. J Am Coll Cardiol (2016) 0.75

TCT-418 Procedural and mid-term outcomes of Bioresorbable scaffOlds versus drug-elutiNg stents In chronic Total Occlusions: the BONITO Registry. J Am Coll Cardiol (2016) 0.75

TCT-394 Impact of inadequate angiographic results after pre-dilatation on clinical outcomes following drug-coated balloon treatment for in-stent restenosis. J Am Coll Cardiol (2016) 0.75

A challenging case of transcatheter aortic prosthesis dysfunction: Endocarditis or thrombosis? Int J Cardiol (2016) 0.75

TCT-436 Multi-Center, Post-marketing Evaluation of the Elixir DESolve® Novolimus Eluting Bioresorbable Coronary Stent System: 6-month Results from the DESolve PMCF Study. J Am Coll Cardiol (2016) 0.75

TCT-41 Up to two years follow up results of mitral valve transcatheter annuloplasty system for mitral reconstruction multi-center trial. J Am Coll Cardiol (2016) 0.75

Erratum: The Practice Pattern of Percutaneous Coronary Intervention in Korea: Based on Year 2014 Cohort of Korean Percutaneous Coronary Intervention (K-PCI) Registry. Korean Circ J (2017) 0.75